ZSTK474 treatment significantly inhibited tumor growth, but depletion of either CD4+ T cells or CD8+ T cells abrogated the antitumor effects of ZSTK474, indicating that both CD4+ T cells and CD8+ T cells contribute to tumor growth inhibition by ZSTK474 (figure 1C). Here, CD4 is linked to neoplasm.